

# MATERIAL SAFETY DATA SHEET

Pharmaceutical Research Laboratories Inc. • PO BOX 369, Naugatuck, CT 06770  
(203) 755-4908 • 800-243-5350 • FAX (203) 7554309  
www.pharmaceutical.com



OXIDIZER

DATE OF ISSUE 03/16/2012

## HMIS

Not Established

## I. PRODUCT IDENTIFICATION

PRODUCT NAME:

**CLIDOX-S® DILUTION**  
**EPA Reg # 8714-8**

MANUFACTURER:

PHARMACAL RESEARCH LABS., INC.  
562 Captain Neville Drive  
Waterbury, CT 06705

**EMERGENCY TELEPHONE NUMBERS:**  
**CHEMTREC**  
**IN CANADA CALL CANUTEC**

**FOR CHEMICAL EMERGENCY**  
**1-800-424-9300**  
**1-613-996-6666**

## II. COMPONENTS AND HAZARD INFORMATION

PRODUCT IS MIXED ON SITE. CONSULT CLIDOX-S® BASE AND CLIDOX-S® ACTIVATOR MATERIAL SAFETY DATA SHEETS PRIOR TO USE.

MIXTURE OF BASE + WATER + ACTIVATOR = ACIDIFIED SODIUM CHLORITE

CHLOROUS ACID + CHLORINE DIOXIDE

### WARNING STATEMENTS

**CAUTION:** May cause eye irritation. Harmful if swallowed. Do not get in eyes, on skin, or on clothing. Wash thoroughly with soap and water after handling. Wash contaminated clothing before reuse.

## III. EMERGENCY AND FIRST AID PROCEDURES

If in eyes:	<ul style="list-style-type: none"><li>• Hold eye open and rinse slowly and gently with water for 15 - 20 minutes.</li><li>• Remove contact lenses, if present, after the first five minutes, then continue rinsing eye.</li><li>• Call a poison control center or doctor for treatment advice.</li></ul>
If swallowed:	<ul style="list-style-type: none"><li>• Call a poison control center or doctor immediately for treatment advice.</li><li>• Have person drink large quantities of water if able to swallow.</li><li>• Do not induce vomiting unless told to do so by the poison control center or doctor.</li><li>• Do not give anything by mouth to an unconscious person.</li></ul>
If on skin or clothing:	<ul style="list-style-type: none"><li>• Take off contaminated clothing.</li><li>• Rinse skin immediately with plenty of water for 15 - 20 minutes.</li><li>• Call a poison control center or doctor for treatment advice.</li></ul>
Inhalation	<ul style="list-style-type: none"><li>• Move to fresh air.</li><li>• Consult a physician if irritation of respiratory passages occur.</li></ul>

# MATERIAL SAFETY DATA SHEET

Pharmacal Research Laboratories Inc. • PO BOX 369, Naugatuck, CT 06770  
(203) 755-4908 • 800-243-5350 • FAX (203) 7554309  
www.pharmacal.com

## **IV. FIRE AND EXPLOSION DATA**

### **HANDLING PRECAUTIONS:**

KEEP CONTAINER COOL BY SPRAYING WITH WATER IF EXPOSED TO FIRE.  
STORE AWAY FROM HEAT.

### **EXTINGUISHING MEDIA AND FIRE FIGHTING PROCEDURES:**

APPROACH FIRE FROM UPWIND TO AVOID HAZARDOUS VAPORS & TOXIC  
DECOMPOSITION PRODUCTS. WEAR SELF-CONTAINED BREATHING  
APPARATUS.

EXTINGUISH WITH WATER.

### **DECOMPOSITION PRODUCTS UNDER FIRE CONDITIONS:**

MAY REACT WITH COMBUSTIBLE SUBSTANCE CREATING FIRE OR EXPLOSION  
HAZARD. CAN RELEASE CHLORINE DIOXIDE.

## **V. HEALTH AND HAZARD INFORMATION**

### **EFFECTS OF OVEREXPOSURE / SIGNS AND SYMPTOMS OF EXPOSURE:**

INHALATION IRRITATING, SKIN IRRITATING, INGESTION TOXIC

### **NATURE OF HAZARD AND TOXICITY INFORMATION:**

INHALATION	EPA CATEGORY IV LC50 > 2.01 mg/L
ACUTE ORAL TOXICITY	GREATER THAN 5g/kg
SKIN IRRITATION	MATERIAL IS A NON-PRIMARY IRRITANT
Primary dermal irritation index	0.34
EYE IRRITATION	MATERIAL IS PRACTICALLY NON-IRRITATING
mean maximum score	0.7

## **VI. PHYSICAL DATA**

THE FOLLOWING DATA ARE APPROXIMATE OR TYPICAL VALUES AND SHOULD NOT BE USED FOR PRECISE  
DESIGN PURPOSES.

BOILING POINT	100°C
<b>pH</b>	
1:5:1 DILUTION	1.5 - 3.5
1:18:1 DILUTION	2 - 4
PRODUCT APPEARANCE	BRIGHT YELLOW LIQUID

## **VII. REACTIVITY**

AVOID HEAT - TEMPERATURES ABOVE 100 °F SHOULD BE AVOIDED.  
AVOID STRONG ALKALI (BASES).

**CLIDOX-S® DILUTION**

PAGE 2 of 3

# MATERIAL SAFETY DATA SHEET

Pharmacal Research Laboratories Inc. • PO BOX 369, Naugatuck, CT 06770  
(203) 755-4908 • 800-243-5350 • FAX (203) 7554309  
www.pharmacal.com

## **VIII. SPILL, LEAK, AND DISPOSAL PROCEDURES**

### **STEPS TO BE TAKEN IN CASE MATERIAL IS RELEASED OR SPILLED:**

CONTAIN SPILLED MATERIAL IN SUITABLE CONTAINERS OR HOLDING AREA. FLUSH WITH PLENTY OF WATER. DISPOSE INTO TREATMENT SYSTEM IN ACCORDANCE WITH FEDERAL, STATE, AND LOCAL LAWS.

### **“EMPTY” CONTAINER WARNINGS:**

TRIPLE RINSE WITH WATER - DISPOSE OF IN CONFORMANCE WITH FEDERAL, STATE, AND LOCAL REGULATIONS.

## **IX. PROTECTION AND PRECAUTIONS**

### **VENTILATION:**

GOOD VENTILATION TO KEEP HAZARDOUS INGREDIENTS BELOW TLV

### **RESPIRATORY PROTECTION:**

NIOSH APPROVED ACID MIST RESPIRATOR SUITABLE FOR CHLORINE IF THERE IS A REASONABLE POSSIBILITY OF EXPOSURE

### **PROTECTIVE GLOVES:**

COMPATIBLE CHEMICAL RESISTANT GLOVES.

NITRILE GLOVES (4- TO 5-MIL THICKNESS) FOR USE AT THE 1:5:1 OR LESSER DILUTION WITH A MAXIMUM SUSTAINED CONTACT TIME OF 30 MINUTES. BEYOND 30 MINUTES OF EXPOSURE, NITRILE GLOVES SHOULD BE CHANGED TO A NEW PAIR OF SIMILAR THICKNESS.

### **EYE PROTECTION:**

CHEMICAL SAFETY GOGGLES OR FACESHIELD

### **OTHER PROTECTIVE EQUIPMENT:**

APRON - SOLUTION MAY STAIN CLOTHING

### **PERSONAL HYGIENE:**

DO NOT GET INTO EYES, ON SKIN OR CLOTHING - WASH THOROUGHLY AFTER USE

## **X. TRANSPORTATION INFORMATION**

TRANSPORTATION INCIDENT INFORMATION: NOT TRANSPORTED IN THIS FORM

DOT IDENTIFICATION NUMBER N/A

SHIPPING DESCRIPTION NOT TRANSPORTED IN THIS FORM

THE INFORMATION AND RECOMMENDATIONS CONTAINED HEREIN ARE, TO THE BEST OF PHARMACAL'S KNOWLEDGE AND BELIEF, ACCURATE AND RELIABLE AS OF THE DATE ISSUED. PHARMACAL DOES NOT WARRANT OR GUARANTEE THEIR ACCURACY OR RELIABILITY, AND PHARMACAL SHALL NOT BE LIABLE FOR ANY LOSS OR DAMAGE ARISING OUT OF THERE USE THEREOF.

THE INFORMATION AND RECOMMENDATIONS ARE OFFERED FOR THE USER'S CONSIDERATION AND EXAMINATION, AND IT IS THE USER'S RESPONSIBILITY TO SATISFY ITSELF THAT THEY ARE SUITABLE AND COMPLETE FOR ITS PARTICULAR USE.

THE HAZARDOUS MATERIALS IDENTIFICATION SYSTEM (HMIS) AND NATIONAL FIRE PROTECTION ASSOCIATION RATINGS HAVE BEEN INCLUDED BY PHARMACAL RESEARCH LABORATORIES INC. IN ORDER TO PROVIDE ADDITIONAL HEALTH AND HAZARD INFORMATION. THE RATINGS RECOMMENDED ARE BASED UPON CRITERIA SUPPLIED BY THE DEVELOPERS OF THESE RATING SYSTEMS, TOGETHER WITH PHARMACAL'S INTERPRETATION OF THE AVAILABLE DATA.